Health

COVID-19 and the vaccine: Taking stock of how the Indian government has responded to the pandemic

COVID-19 and the vaccine: Taking stock of how the Indian government has responded to the pandemic
Written by admin
COVID-19 and the vaccine: Taking stock of how the Indian government has responded to the pandemic

COVID-19 and the vaccine: Taking inventory of how the Indian authorities has responded to the pandemic

As of 28 November, India has 6,731 circumstances per million inhabitants, in keeping with the Union well being ministry’s knowledge. As compared, USA has 40,000 circumstances per million and UK has 23,361.

COVID-19 and the vaccine: Taking stock of how the Indian government has responded to the pandemic

Representational picture. AFP

Almost eleven months after the novel coronavirus outbreak started in India, there might lastly be some trigger for cheer — within the type of the vaccine being developed by AstraZeneca and the College of Oxford.

The vaccine is anticipated to obtain approval by the tip of the yr, and could also be launched in January, in keeping with an article in Mint.

On Saturday, Prime Minister Narendra Modi is slated to go to Ahmedabad, Hyderabad and Pune to assessment the event of the vaccines towards coronavirus . He’s scheduled to go to the Zydus Biotech Park in Ahmedabad, Bharat Biotech in Hyderabad and Serum Institute of India in Pune. Two of those websites are the place India is indigenously creating vaccines to combat COVID-19 and considered one of these websites (Ahmedabad) is the place the vaccine will probably be manufactured.

Pune Divisional Commissioner Saurabh Rao has additionally been quoted as saying by PTI that ambassadors and envoys from 100 nations will go to the Serum Institute of India and the Gennova Biopharmaceuticals Ltd in Pune on 4 December.

COVID19 and the vaccine Taking stock of how the Indian government has responded to the pandemic

On this context, right here is an outline of the place India stands within the combat towards COVID-19 and the steps the federal government took since Modi introduced a nationwide lockdown on 24 March, and a short take a look at the standing of vaccines beneath improvement.

 

Case load

As of 28 November, India has 6,731 circumstances per million inhabitants, in keeping with the Union well being ministry’s knowledge. As compared, USA has 40,000 circumstances per million, UK has 23,361, France has 33,424, Brazil has 29,129 whereas Italy has 25,456. Most of those nations have about 4-5 occasions the variety of circumstances than India, on a per million foundation.

In terms of variety of deaths per million inhabitants. India noticed 98 deaths per million inhabitants.​ As compared, the US noticed 813, Brazil noticed 805, France noticed 780, Spain noticed 955, UK noticed 846 and Italy 888. Nevertheless, as of 18 November, neighbouring Pakistan and Bangladesh had decrease demise charges than India, in keeping with an evaluation by BBC.

Impact on economic system and aid measures

The COVID-19 lockdown additionally prompted immense monetary misery throughout the nation. To tide over this, the federal government introduced free meals grains and money cost by means of the Rs 1.70 lakh crore Pradhan Mantri Garib Kalyan Bundle (PMGKP), in keeping with the Union finance ministry.

The Indian economic system contracted by 7.5 p.c within the July-September quarter of this fiscal amid the COVID-19 disaster, official knowledge confirmed on Friday.

The gross home product (GDP) had expanded by 4.4 p.c within the corresponding July-September interval of 2019-20, in keeping with knowledge launched by the Nationwide Statistical Workplace (NSO).

Vaccines

The efficacy of AstraZeneca and Oxford’s vaccine, recognized formally as AZD1222, has diversified in trials, relying on the mixture of doses administered. The vaccine was discovered to convey the variety of symptomatic COVID-19 circumstances down by 90 p.c in those that obtained half a dose of the vaccine adopted by a full dose a month later. Nevertheless, the efficacy decreased to 62 p.c when the vaccine was administered as two full doses at the very least a month aside.

An article in The Indian Specific quoted Okay Srinath Reddy, President of the Public Well being Basis of India, as saying, “I’d say that it’s attainable {that a} decrease dose publicity initially primes the system significantly better, and the second dose takes the physique’s immune response to a a lot larger degree, however that is speculative.”

The Astrazeneca-Oxford vaccine specifically holds out hope for India, as it may be saved at temperatures of two levels Celsius to eight levels Celsius and will probably be priced at USD 3 a dose for the federal government — comparatively less expensive than different vaccine candidates.

In the meantime, Russia’s vaccine candidate Sputnik V has claimed efficacy of over 95 p.c 42 days after the primary dose.

Apart from the Oxford-AstraZeneca and the Sputnik V developed by Russia’s Gamaleya Analysis Institute, two different vaccine candidates have additionally introduced their efficacy charges. The Pfizer-BioNTech’s BNT162b2 has 95 p.c efficacy whereas Moderna-NIH candidate mRNA-1273 is greater than 90 p.c efficient.

Presently, there are 11 vaccine candidates on the final stage of section III trials, together with the 4 named above. General, as per the newest knowledge launched by the WHO on COVID-19 vaccines (final up to date on 12 November 2020), there are 48 candidate vaccines present process medical analysis at varied levels, whereas, 164 candidate vaccines are in preclinical analysis.

With inputs from PTI

#COVID19 #vaccine #inventory #Indian #authorities #responded #pandemic

About the author

admin